In conclusion, TMAO likely modulates immune responses in IBD through the activation of the PERK-CHOP and PERK-eIF2α pathways, underscoring the complex interplay of UPR signaling in maintaining intestinal homeostasis and immune function. The gene discussed is DDIT3; the disease is inflammatory bowel disease.